Aparajita Chourasia
Executive Vice President, R&D BioTheryx
Seminars
Wednesday 28th October 2026
BTX-9341, a First-in-Class, Potent & Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer Post-CDK4/6 Inhibitor Therapy – Latest from the Clinic
9:00 am
- BTX-9341-101 Phase 1 study design and patient population
- Safety/tolerability and PK/PD profile of BTX-9341 as monotherapy and in combination with fulvestrant
- Promising clinical activity in a heavily pre-treated patient population post-CDK4/6 inhibitor therapies with high disease burden
